The Influence of Cyclophosphamide on Immune Function of Murine Macrophages

Bryniarski, Krzysztof

doi:10.5772/32891

Cited by 3 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…54 One group analyzed macrophage phenotype and function following administration of cyclophosphamide 50 mg/kg in a murine model. These macrophages showed increased production of pro-inflammatory IL-6 and IL-12 associated with the M1 phenotype, and reduced levels of anti-inflammatory IL-19 and TGF-b, 55 which have been shown to induce immune-suppressive Tregs. 56 A study by Pallasch et al using a malignant B-cell line, resistant to the CD52 monoclonal antibody alemtuzumab, showed that secretion of prostaglandin E2 (PGE2) by the malignant B-cells inhibited macrophage-mediated phagocytosis.…”

Section: Macrophagesmentioning

confidence: 99%

“…One group analyzed macrophage phenotype and function following administration of cyclophosphamide 50 mg/kg in a murine model. These macrophages showed increased production of pro‐inflammatory IL‐6 and IL‐12 associated with the M1 phenotype, and reduced levels of anti‐inflammatory IL‐19 and TGF‐β, 55 which have been shown to induce immune‐suppressive Tregs 56 …”

Section: Immunomodulatory Effectsmentioning

confidence: 99%

See 1 more Smart Citation

Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma

et al. 2020

View full text Add to dashboard Cite

The alkylating agent cyclophosphamide has been used in the treatment of multiple myeloma for over 60 years. At low doses, cyclophosphamide also has significant immunomodulatory activity, which can be used to modify the immunosuppressive tumor microenvironment in order to augment responses to existing therapies. Immune-mediated therapies are becoming more widespread in modern approaches to myeloma treatment. In this review, we discuss the effects cyclophosphamide has on the immune system, and how it can be used synergistically with other treatment modalities including the immunomodulatory agents, monoclonal antibodies and cellular therapies.

show abstract

Section: Macrophagesmentioning

confidence: 99%

Section: Immunomodulatory Effectsmentioning

confidence: 99%

Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Studies have demonstrated that CPA can promote the IL-1b, IL-6 and TNF-α levels [48]. Furthermore, apart from the influence of CPA and its metabolites on the IL-6 production the diminishing of IL-10 production by macrophages [49].…”

Section: Discussionmentioning

confidence: 99%

The MODULATORY EFFECTS OF BONE MARROW-DERIVED MESENCHMAL STEM CELLS ON CYCLOPHOSPHAMIDE INDUCED HEPATOTOXICITY IN CARCINOMA MICE

Zaazaa

El-Motlep

2020

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: Cyclophosphamide (CPA) is a chemotherapeutic agent, induces hepatotoxicity as one of its side effects. Therefore, the present work was designed to investigate the protective role of bone marrow-derived mesenchymal stem cells (BM-MSCs) on CPA–induced hepatotoxicity in Ehrlich Ascites Carcinoma bearing-mice (EAC) and to test whether BM-MSCs influences the antitumor properties of the CPA. Methods: The hepatoprotective effects of BM-MSCs (single dose of 100 µl of a cell suspension containing allogenic BM-MSCs, i. v.) was evaluated in a model of hepatotoxicity by CPA (10 mg/kg/d i. p.) in EAC-female mice for one month. The anti-tumor activities of CPA and BM-MSCs were assessed by measuring mean tumor weight, mean survival time and the increase in life span. Moreover, ALT, AST, GGT, MDA, GSH, SOD, IL-6, IL10, caspase-3 and Bcl2 were measured. Results: The i. p. administration of CPA and BM-MSCs resulted in significant reductions in tumor size and mean tumor weight as well as caused concurrent significant increases in the life span as compared to the EAC mice. Furthermore, BM-MSCs ameliorated the liver enzyme markers namely ALT, AST, GGT, and hepatic oxidative stress through inhibition of MDA level that correlated with significant improvement in antioxidant status via increasing GSH and SOD levels as compared to both EAC and EAC+CPA groups. Moreover, BM-MSCs treatment significantly reduced the inflammatory marker level IL-6 as well as increment the level of IL-10 with subsequent decreases apoptosis via a depletion in the caspase-3 associated with an enhancement in the level of Bcl2 as compared to EAC group and EAC+CPA group. Minor histological lesions were observed in the liver tissue sections of mice treated with CPA and BM-MSCs as compared to the high histological lesions observed in the liver of the EAC group and CPA treated group. Conclusion: These results concluded that the combination treatment of BM-MSCs with CPA exhibited promising potential antitumor efficacy with greater safety than CPA treatment alone in mice via its antioxidant, anti-inflammatory and antiapoptotic effects.

show abstract

“…Патологічні стани, викликані побічною дією циклофосфаміду, іноді зумовлюють неможливість використання заздалегідь ефективних схем лікування [1,4]. Для коректного пошуку модифікаторів токсичності циклофосфаміду необхідні дані про всі складові патологічного процесу, викликаного дією препарату.…”

unclassified

Морфологічні Прояви Реакції Мікроциркуляторного Русла Стінки Тонкої Кишки Щурів В Умовах Дії Циклофосфаміду На Ранніх Термінах

Bondarchuk¹,

Gavrilyuk²

2017

Lik. sprava

View full text Add to dashboard Cite

Дослідження присвячене встановленню морфологічних проявів реакції компонентів мікроциркуляторного русла оболонок тонкої кишки на одноразове введення циклофосфаміду. Експеримент проводили на 36 білих безпородних щурах. Доведено, що в умовах дії циклофосфаміду до третьої доби структура мікроциркуляторного русла не відновлюється, а значення питомої ваги її компонентів достовірно відрізняються від контрольних.

show abstract

The Influence of Cyclophosphamide on Immune Function of Murine Macrophages

Cited by 3 publications

References 21 publications

Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma

Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma

The MODULATORY EFFECTS OF BONE MARROW-DERIVED MESENCHMAL STEM CELLS ON CYCLOPHOSPHAMIDE INDUCED HEPATOTOXICITY IN CARCINOMA MICE

Морфологічні Прояви Реакції Мікроциркуляторного Русла Стінки Тонкої Кишки Щурів В Умовах Дії Циклофосфаміду На Ранніх Термінах

Contact Info

Product

Resources

About